Rosalind Advisors’s ArriVent BioPharma AVBP Stock Holding History

Rosalind Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-215,871	Closed	-$4.88M	–	48
2025 Q4	$4.34M	Buy	+215,871	New	+$4.49M	1.53%	19

Other funds holding AVBP

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rosalind Advisors's AVBP Position: Q1 2026 in Review

Rosalind Advisors sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 215,871 shares — an estimated $4.88M sold.

Rosalind Advisors first reported a position in AVBP in Q4 2025 and held it in 1 quarter. The position peaked at $4.34M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Rosalind Advisors reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
Rosalind Advisors sold 215,871 ArriVent BioPharma shares in Q1 2026, an estimated $4.88M.
Rosalind Advisors first reported a position in ArriVent BioPharma in Q4 2025 and held it in 1 quarter.
Rosalind Advisors's ArriVent BioPharma position peaked at $4.34M in Q4 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.